Floatz logo

175 assets in Breast Neoplasm

Therapeutic assets addressing Breast Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Breast Neoplasm
Merck Sharp & Dohme LLCP4BB (70)
Cyclophosphamide
Breast Neoplasm
Merck Sharp & Dohme LLCP4BB (70)
Docetaxel
Breast Neoplasm
Universitas AirlanggaP4BB (70)
Exemestane
Breast Neoplasm
Fujian Cancer HospitalP4BB (70)
Letrozole
Breast Neoplasm
Fujian Cancer HospitalP4BB (70)
Tamoxifen
Breast Neoplasm
Eli Lilly and CompanyP3BB (70)
Epirubicin
Breast Neoplasm
Universitas AirlanggaP4BB (69)
Eribulin Monomethanesulfonate
Breast Neoplasm
Fudan UniversityP4BB (69)
Palbociclib
Breast Neoplasm
Eli Lilly and CompanyP4BB (69)
Anastrozole
Breast Neoplasm
Fujian Cancer HospitalP4BB (68)
Capecitabine
Breast Neoplasm
Kristina A. FanucciP4BB (68)
Trastuzumab
Breast Neoplasm
Merck Sharp & Dohme LLCP3BB (68)
Fluorouracilum
Breast Neoplasm
Rutgers, The State University of New JerseyP4BB (67)
Pertuzumab
Breast Neoplasm
Merck Sharp & Dohme LLCP4BB (67)
Ropivacaine
Breast Neoplasm
Fudan UniversityP4BB (67)
Carboplatin
Breast Neoplasm
BioNTech SEP3BB (66)
Fulvestrant
Breast Neoplasm
Eli Lilly and CompanyP4BB (66)
Oxaliplatin
Breast Neoplasm
Kristina A. FanucciP3BB (66)
L-Bupivacaine
Breast Neoplasm
University Hospital, AntwerpP4BB (65)
Sacubitril Valsartan
Breast Neoplasm
Silesian Centre for Heart DiseasesP4BB (65)
Abemaciclib
Breast Neoplasm
Eli Lilly and CompanyP4BB (64)
Goserelin
Breast Neoplasm
Eli Lilly and CompanyP4BB (64)
Sv-Br-1-Gm
Breast Neoplasm
BriaCell Therapeutics CorporationP3BB (64)
Eribulin
Breast Neoplasm
BioNTech SEP4B (63)
Leuporelin
Breast Neoplasm
Eli Lilly and CompanyP4B (63)
Ribociclib
Breast Neoplasm
Eli Lilly and CompanyP4B (63)
Olaparib
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (62)
Retifanlimab
Breast Neoplasm
BriaCell Therapeutics CorporationP3B (62)
Vinorelbine Ditartrate
Breast Neoplasm
Sun Yat-sen UniversityP3B (62)
Everolimus
Breast Neoplasm
Fudan UniversityP4B (61)
Lidocaine
Breast Neoplasm
Chinese University of Hong KongP4B (61)
Imlunestrant
Breast Neoplasm
Eli Lilly and CompanyP3B (60)
Irinotecan
Breast Neoplasm
Wang JiayuP3B (60)
Marcaine
Breast Neoplasm
Medipol UniversityP4B (60)
Neratinib
Breast Neoplasm
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3B (60)
Nivolumab
Breast Neoplasm
Providence Health & ServicesP2B (60)
Patritumab Deruxtecan
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Peg-G-Csf
Breast Neoplasm
Kexing Biopharm Co., Ltd.P3B (60)
Pembrolizumab
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Lapatinib
Breast Neoplasm
Deraya UniversityP3B (59)
Trastuzumab Emtansine
Breast Neoplasm
Pierre Fabre Pharma GmbHP3B (59)
Artiss
Breast Neoplasm
Mid and South Essex NHS Foundation TrustP4B (58)
Disitamab Vedotin
Breast Neoplasm
PfizerP2/3B (58)
Talazoparib
Breast Neoplasm
PfizerP3B (58)
Catequentinib
Breast Neoplasm
Fudan UniversityP2B (57)
Denosumab
Breast Neoplasm
Alliance for Clinical Trials in OncologyP3B (57)
Famitinib
Breast Neoplasm
Fudan UniversityP2B (57)
Rivoceranib
Breast Neoplasm
Fudan UniversityP2B (57)
Sorafenib
Breast Neoplasm
Fudan UniversityP2B (57)
Eflapegrastim
Breast Neoplasm
Eunseong Medical Foundation Good GANG-AN HOSPITALP4B (56)
Showing 1 to 50 of 175 assets
PreviousPage 1 of 4Next